Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers
NCT ID: NCT04159961
Last Updated: 2024-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2019-12-24
2020-04-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers
NCT07144176
Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315
NCT06592495
Pharmacokinetics and Safety Following Administration of DWP16001
NCT05414591
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers
NCT06119945
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1567 in Healthy Adult Volunteers
NCT06109259
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GroupA
Inject the Drug into submental fat and abdominal fat via subcutaneous
DWJ211
Inject the Drug into submental fat and abdominal fat via subcutaneous
GroupB
Inject the Drug into submental fat and abdominal fat via subcutaneous
DWJ211
Inject the Drug into submental fat and abdominal fat via subcutaneous
GroupC
Inject the Drug into submental fat and abdominal fat via subcutaneous
DWJ211
Inject the Drug into submental fat and abdominal fat via subcutaneous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DWJ211
Inject the Drug into submental fat and abdominal fat via subcutaneous
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those whose BMI is less than 40kg/m2
* Subject who will agree with the no treatment(liposuction or surgery, obesity treatment)
* Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc
Exclusion Criteria
* History of any intervention to treat Submental fat or abdominal fat
* History or current symptoms of dysphagia
* History of trauma associated with the chin or neck or abdominal areas that in the judgement of the investigator may affect evaluation of safety or efficacy of treatment
19 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWJ211101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.